rd
[1] Kane, M.D. 3 International Symposium on Early Toxicity Screening. Expert Opin. Drug Saf., 2003, 2, 199-201.
[2] Kola, I.; Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature Rev., 2004, 3, 711-715.
[3] Wienkers, L.C.; Heath, T.G. Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug Dis., 2005, 4, 825-833.
[4] Ito, K.; Brown, H.S.; Houston, J.B. Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br. J. Clin. Pharm., 2003, 57, 473-486.
[5] Ito, K.; Hallifax, D.; Obach, R.S.; Houston, J.B. Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab. Dispos., 2005, 33, 837-844.
[6] McKim, Jr. J.M.; Wilga, P.C.; Kolesar, G.B.; Choudhuri, S.; Madan, A.; Dochterman, L.W.; Breen, J.G.; Parkinson, A.; Mast, R.W.; Meeks, R.G. Evaluation of octamethylcyclotetrasiloxane (D4) as an inducer of rat hepatic microsomal cytochrome P450, UDP-glucuronosyltransferase, and epoxide hydrolase: a 28-day inhalation study. Toxicol. Sci., 1998, 41, 29-41.
[7] McKim, Jr. J.M.; Kolesar, G.B.; Jean, P.A.; Meeker, L.S.; Wilga, P.C.; Schoonhoven, R.; Swenberg, J.A.; Goodman, J.I.; Gallavan, R.H.; Meeks, R.G. Repeated inhalation exposure to octamethylcyclotetrasiloxane produces hepatomegaly, transient hepatic hyperplasia, and sustained hypertrophy in female Fischer 344 rats in a manner similar to phenobarbital. Toxicol. Appl. Pharmacol., 2001, 172, 83-92.
[8] Tillitt, D.E.; Ankley, G.T.; Verbrugge, D.A.; Giesy, J.P.; Ludwig, J.P.; Kubiak, T.J. H4IIE Rat hepatoma cell bioassay-derived 2,3,7,8,-tetrachlorodibenzo-p-dioxin equivalents in colonial fish- eating waterbird eggs from the great lakes. Arch. Environ. Contam. Toxicol., 1991, 21, 91-101.
[9] Kopponen, P.; Törrönen, R.; Mäki-Paakkanen, J.; von Wright, A.; Kärenlampi, S. Comparison of CYP1A1 induction and genotoxicity in vitro as indicators of potentially harmful effects of environmental samples. Arch. Toxicol., 1994, 68, 167-173.
[10] Machala, M.; Blaha, L.; Lehmler, H.J.; Pliskova, M.; Májková, Z.; Kapplová, P.; Sovadinová, I.; Vondrácek, J.; Malmberg, T.; Robertson, L.W. Toxicity of hydroxylated and quinoid PCB metabolites: inhibition of gap junctional intercellular communication and activation of aryl hydrocarbon and estrogen receptors in hepatic and mammary cells. Chem. Res. Toxicol., 2004, 17, 340-347.
[11] Villeneuve, D.L.; Kannan, K.; Khim, J.S.; Falandysz, J.; Nikiforov, V.A.; Blankenship, A.L.; Giesy, J.P. Relative potencies of individual polychlorinated naphthalenes to induce dioxin-like responses in fish and mammalian in vitro bioassays. Arch. Environ. Contamin. Toxicol., 2000, 39, 273-281.
[12] Li, X.; Qu, Z.C.; May, J.M. GSH is required to recycle ascorbic acid in cultured liver cell lines. Antioxid. Redox. Signal, 2001, 3, 1089-1097.
[13] Mehta, R.; Davis, H.G.; Laver, G.W.; Rowsell, P.R.; Bondy, G.S. Glutathione S-transferases and P-glycoprotein in normal rat hepatocytes and hepatoma cells: analysis using flow cytometry. Cancer Letter, 1995, 89, 231.
[14] Swedmark, S.; Romert, L.; Morgenstern, R.; Jenssen, D. Studies on glutathione transferases belonging to class pi in cell lines with 
[15] Yang, H.; Magilnick, N.; Ou, X.; Lu, S.C. Tumour necrosis factor induces co-ordinated activation of rat GSH synthetic enzymes via nuclear factor B and activator protein-1. Biochem. J., 2005, 391, 399-408
[16] Valera, A.; Bosch, F. Glucokinase Expression in rat hepatoma cells induces glucose uptake and is rate limiting in glucose utilization. Eur. J. Biochem., 1994, 222, 533-539.
[17] Brown, N.F.; Stefanovic-Racic, M.; Sipula, I.J.; Perdomo, G. The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes. Metab. Clin. Exp., 2007, 56, 1500-1507.
[18] Hewitt, N.J.; Lechón, M.J.; Houston, J.B.; Hallifax, D.; Brown, H.S.; Maurel, P.; Kenna, J.G.; Gustavsson, L.; Lohmann, C.; Skonberg, C.; Guillouzo, A.; Tuschl, G.; Li, A.P.; LeCluyse, E.; Groothuis, G.M.; Hengstler, J.G. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab. Rev., 2007, 39, 159-234.
[19] Wilkening, S.; Stahl, F.; Bader, A. Comparison of primary human hepatocytes and hepatoma cell Line HEPG2 with regard to their biotransformation properties. Drug Metab. Dis., 2003, 31, 1035- 1042.
[20] Naritomi, Y.; Terashita, S.; Kagayama, A.; Sugiyama, Y. Utility of hepatocyters in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab. Disp., 2003, 31, 580-588.
[21] Kienhuis, A.S.; Wortelboer, H.M.; Maas, W.J.; Van Herwijnen, M.; Kleinjans, J.C.S.; Van Delft, J.H.M.; Stierum, R.H. A sandwich-cultured rat hepatocyte system with increased metabolic competence evaluated by gene expression profiling. Toxicol. In vitro, 2007, 21, 892-901.
[22] Kostrubsky, S.E.; Strom, S.C.; Kalgutkar, A.S.; Kulkarni, S.; Atherton, J.; Mireles, R.; Feng, B.; Kubik, R.; Hanson, J.; Urda, E.; Mutlib, A.E. Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone, Toxicol. Sci., 2006, 90, 451-459.
[23] Maggs, J.L.; Bishop, L.P.D.; Batty, K.T.; Dodd, C.C.; Ilett, K.F.; O’Neill, P.M.; Edwards, G.; Park, B.K. Hepatocellular bioactivation and cytotoxicity of the synthetic endoperoxide antimalarial arteflene. Chem. Biol. Inter., 2004, 147, 173-184.
[24] Kaminski, N.E.; Stevens, W.D. The role of metabolism in carbon tetrachloride-mediated immunosuppression. In vitro Toxicol., 1992, 75, 175-188.
[25] Heinonen, J.T.; Sidhu, J.S.; Reilly, M.T.; Farin, F.M.; Omiecinski, C.J.; Eaton, D.L.; Kavanagh, T.J. Assessment of regional cytochrome P450 activities in rat liver slices using resorufin substrates and fluorescence confocal laser cytometry. Environ. Health Perspect., 1996, 104, 536-543.
[26] Lup, A.; Glockner, R.; Danz, M.; Muller, D. Cryopreserved precision-cut rat liver slices, morphology and cytochrome P450 isoforms expression after prolonged incubation. Toxicol. In vitro, 2002, 16, 749-758.
[27] Neyrinck, A.M.; Margagliotti, S.; Delzenne, N.M. Insight into the involvement of Kupffer cell-derived mediators in the hepatoprotective effect of glycine upon inflammation: study on rat precision-cut liver slices. Inflamm. Res., 2005, 54, 106-112.
[28] Neyrinck, A.M.; Alexiou, H.; Delzenne, N.M. Kupffer cell activity is involved in the hepatoprotective effect of dietary oligofructose in rats, with endotoxic shock. J. Nutr., 2004, 134, 1124-1129.
[29] Neyrinck, A.M.; Taper, H.S.; Gevers, V.; Declerck, B.; Delzenne, N.M. Inhibition of Kupffer cell activity induces hepatic triglyceride synthesis in fasted rats, independent of lipopolysaccharide challenge. J. Hepatol., 2002, 36, 466-473.
[30] Elferink, G.L.; Olinga, P.; Draaisma, A.L.; Merema, T.; Faber, K.N.; Stooff, M.J.H.; Meijer, D.K.F.; Groothuis, G.M.M. LPS- induced Downregulation of MRP2 and BSEP in human liver is due to a posttranscriptional process. Am. J. Physiol. Gastrointest. Liver Physiol., 2004, 287, 1008-1016.
[31] Melgert, B.N.; Olinga, P.; Jack, V.K.; Molema, G.; Meijer, D.K.F.; Poelstra, K. Dexamethasone coupled to albumin is selectively taken 
[32] Amin, K.; Ip, C.; Sato, B.; Le, T.; Green, C.E.; Tyson, C.A.; Behrsing, H.P. Characterization of ANIT-induced toxicity using precision-cut rat and dog liver slices cultured in a dynamic organ roller system. Toxicol. Pathol., 2006, 34, 776-784.
[33] Vickers, A.E.M.; Fisher, R.L. Precision-cut organ slices to investigate target organ injury. Exp. Opin. Drug Metab. Toxicol., 2005, 1, 687-699.
[34] Parrish, A.R.; Gandolfi, A.J.; Brendel, K. Minireview precision-cut tissue slices: applications in pharmacology and toxicology. Life Sci., 1995, 57, 1886-1901.
[35] Lerche-Langrand, C.; Toutain, H.J. Precision-cut liver slices: characteristics and use for in vitro pharmaco-toxicology. Toxicology, 2000, 153, 221-253.
[36] Rodrigues, A.D.; Ferrero, J.L.; Amann, M.T.; Rotert, G.A.; Cepa, S.P.; Surber, B.W.; Machinist, J.M.; Tich, N.R.; Sullivan, J.P.; Garvey, D.S.; Fitzgerald, M.; Arneric, S.P. The in vitro hepatic metabolism of ABT-418, a cholinergic channel activator, in rats, dogs, Cynomolgus monkeys, and humans. Drug Metab. Disp., 1994, 22, 788-798.
[37] Catania, J.M.; Pershing, A.M.; Gandolfi, A.J. Precision-cut tissue chips as an in vitro toxicology system. Toxicol. In vitro, 2007, 21, 956-961.
[38] De Graaf, I.A.M.; Draaisma, A.L.; Schoeman, O.; Fahy, G.M.; Groothuis, G.M.M.; Koster, H.J. Cryopreservation of rat precision- cut liver and kidney slices by rapid freezing and vitrification. Cryobiology, 2007, 54, 1-12.
[39] Maas, W.J.M.; de Graff, I.A.M.; Schoen, E.D.; Koster, H.J.; van de Sandt, J.J.M.; Groten, J.P. Assessment of some critical factors in the freezing technique for the cryopreservation of Precision-cut rat liver slices. Cryobiology, 2000, 40, 250-263.
[40] Maas, W.J.M.; Leeman, W.R.; Groten, J.P.; Van De Sandt, J.M. Cryopreservation of precision-cut rat liver slices using a computer- controlled freezer. Toxicol. In Vitro, 2000, 14, 523-530.
[41] Toutain, H.J.; Moronvalle-Halley, V.; Sarsat, J.P.; Chelin, C.; Hoet, D.; Leroy, D. Morphological and functional integrity of precision- cut rat liver slices in rotating organ culture and multiwell plate culture: effects of oxygen tension. Cell Biol. Toxicol., 1998, 14, 175-190.
[42] McKim Jr. JM, Wilga PC, Pregenzer JF, Petrella DK. A biochemical approach to in vitro toxicity testing. Pharma Disc. 2005, 5, 30-34.
[43] Cockerell, G.L.; McKim, J.M.; Vonderfecht, S.L. Strategic importance of research support through pathology. Toxicol. Pathol., 2002, 30, 4-7.
[44] Hamid, R.; Rotshteyn, Y.; Rabadi, L.; Parikh, R.; Bullock, P. Comparison of Alamar Blue and MTT assays for high through-put screening. Toxicol. In Vitro, 2004, 18, 703-710.
[45] Gonzalez, R.J.; Tarloff, J.B. Evaluation of hepatic subcellular fractions for Alamar Blue and MTT reductase activity. Toxicol. In Vitro, 2001, 15, 257-259.
[46] White, M.J.; DiCaprio, M.J.; Greenberg, D.A. Assessment of neuronal viability with Alamar Blue in cortical and granule cell cultures. J. Neurosci. Methods, 1996, 70, 195-200.
[47] Abe, T.; Takahashi, S.; Fukuuchi, Y. Reduction of Alamar Blue, a novel redox indicator, is dependent on both the glycolytic and oxidative metabolism of glucose in rat cultured neurons. Neurosci. Lett., 2002, 326, 179-182.
[48] Roccaro, A.M.; Vacca, A.; Ribatti, D. Bortezomib in the treatment of cancer. Recent Pat. Anticancer Drug Discov., 2006, 1, 397-403.
[49] Dorsey, B.D.; Iqbal, M.; Chatterjee, S.; Menta, E.; Bernardini, R.; Bernareggi, A.; Cassara, P.G.; D’Arasmo, G.; Ferretti, E.; De Munari, S.; Oliva, A.; Pezzoni, G.; Allievi, C.; Strepponi, I.; Ruggeri, B.; Ator, M.A.; Williams, M.; Mallamo, J.P. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J. Med. Chem., 2008, 51, 1068-1072.
[50] Sorolla, A.; Yeramian, A.; Dolcet, X.; Pérez de Santos, A.M.; Liobet, D.; Schoenenberger, J.A.; Casanova, J.M.; Soria, X.; Egido, R.; Llombart, A.; Vilella, R.; Matias-Guiu, X.; Marti, R.M. Effect of proteasome inhibitors on proliferation and apoptosis of human 
[51] Uraz, S.; Tahan, V.; Avgun, C.; Eren, F.; Unluguzel, G.; Yuksel, M.; Senturk, O.; Avsar, E.; Haklar, G.; Celikel, C.; Hulagu, S.; Tozun, N. Role of ursodeoxycholic acid in prevention of methotrexate-induced liver toxicity. Dig. Dis. Sci., 2008, 53, 1071- 1077.
[52] Van Outryve, S.; Schrijvers, D.; van den Brande, J.; Wilmes, P.; Bogers, J.; van Marck, E.; Vermorken. J.B. Methotrexate- associated liver toxicity in a patient with breast cancer: case report and literature review. Neth. J. Med., 2002, 60, 216-222.
[53] Rebora, A. Is methotrexate liver toxicity modest worldwide? Br. J. Dermatol., 1996, 135, 1003-1004.
[54] O’Brien, P.J.; Irwin, W.; Diaz, D.; Howard-Cofield, E.; Krejsa, C.M.; Slaughter, M.R.; Gao, B.; Kaludercic, N.; Angeline, A.; Bernardi, P.; Brain, P.; Hougham, C. High concordance of drug- induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol., 2006, 80, 580-604.
[55] Rodriguez, R.J.; Acosta, Jr. D. Comparison of ketoconazole and fluconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes. Toxicol., 1995, 96, 83-92.
[56] Rodriguez, R.J.; Acosta, Jr. D. Inhibition of mitochondrial function in isolated rat liver mitochondria by azole antifungals. J. Biochem. Toxicol., 1996, 11, 127-131.
[57] Venkatakrishnan, K.; von Moltke, L.L.; Greenblatt, D.J. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin. Pharmacokin., 2000, 38, 111-190.
[58] Kang, B.C.; Yang, C.Q.; Cho, H.K.; Suh, O.K.; Shin, W.G. Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. Biopharam. Drug Disp., 2002, 23, 77-81.
[59] Masubuchi, Y.; Horie, T. Toxicological significance of mechanism-based inactivation of cytochrome P450 enzymes by drugs. Crit. Rev. Toxicol., 2007, 37, 389-412.
[60] Bergstrom, R.F.; Goldberg, M.J.; Cerimele, B.J.; Hatcher, B.L. Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine. Clin Pharm Therap, 1997, 62, 643-651.
[61] Chen, C. Some pharmacokinetic aspects of the lipophilic terfenadine and zwitterionic rexofenadine in humans. Drugs R D., 2007, 8, 301-314.
[62] Harris, S.; Hilligoss, D.M.; Colangelo, P.M.; Eller, M.; Okerholm, R. Azithromycin and terfenadine: lack of drug interaction. Clin. Pharm. Therap., 1995, 58, 310-315.
[63] Lindup, W.E.; Orme, M.L.E Plasma protein binding of drugs. Br. Med. J., 1981, 282, 212-214.
[64] Komissarova, E.V.; Saha, S.K.; Rossman, T.G. Dead or dying: the importance of time in cytotoxicity assays using arsenite as an example. Toxicol. Appl. Pharmacol., 2005, 202(1), 99-107.
[65] De Boer, N.K.H.; Mulder, C.J.J.; van Bodegraven, A.A. Myelotoxicity and hepatotoxicity during azathioprine therapy. Netherlands J. Med., 2005, 63, 444-446.
[66] Petit, E.; Langouet, S.; Akhdar, H.; Nicolas-Nicolaz, C.; Guillouzo, A.; Morel, F. Differential Toxic Effects of azathioprine, 6- mercaptopurine and 6-thioguanine on human hepatocytes. Toxicol. In vitro, 2008, 632-642.
[67] Chan, K.; Truong, D.; Shangari, N.; O’Brien, P. Drug-induced mitochondrial toxicity. Exp. Opin. Drug Metab. Toxicol., 2005, 1, 655-669.
[68] Tapner, M.J.; Jones, B.E.; Wu, W.M.; Farrell, G.C. Toxicity of low dose azathioprine and 6-mercaptopurine in rat hepatocytes. Roles of xanthine oxidase and mitochondrial injury. J. Hepatol., 2004, 40, 454-453.
[69] Lee, A.U.; Farrell, G.C. Mechanism of azathioprine-induced injury to hepatocytes: roles of glutathione depletion and mitochondrial injury. J. Hepatol., 2001, 35(6), 756-764.